IDO1 and melanoma: Although checkpoint inhibitors have revolutionized the treatment for some cancers such as melanoma, not all types of cancer respond due to their lack of PD-L1 expression, Furthermore, some cancers face additional hurdles due to the immunosuppressive effect of indoleamine-2,3-dioxygenase (IDO) expression.